Chronic infections with hepatitis B and hepatitis C

Size: px
Start display at page:

Download "Chronic infections with hepatitis B and hepatitis C"

Transcription

1 Original Article / Liver The impact of family history of hepatocellular carcinoma on its patients' survival Wing Chiu Dai, Sheung Tat Fan, Tan To Cheung, Kenneth SH Chok, Albert CY Chan, Simon HY Tsang, Ronnie TP Poon and Chung Mau Lo Hong Kong, China BACKGROUND: Family history of hepatocellular carcinoma (HCC) has been identified as a risk factor for the development of the disease. The aim of this study is to evaluate the impact of such a history on HCC patients' survival. METHODS: Data of all HCC patients (n=4532) managed at our center from 1989 to 2008 were prospectively collected. The patients were quizzed on their various characteristics including family HCC history. RESULTS: Totally 475 (10.48%) patients had a family history of HCC. They presented the disease at a significantly earlier age (median 53 vs 59 years, P<0.0001) and at an earlier stage (the United Network for Organ Sharing staging system). They had significantly better liver function in terms of Child- Pugh classification and serum albumin and bilirubin levels. Significantly more of them presented the disease without symptoms (44.0% vs 29.4%, P<0.0001). They also had significantly better overall survival under these specifications: patients in the whole study cohort, patients who had minor hepatectomy, patients with stage I disease, patients with stage II disease, and patients with stage III disease. CONCLUSIONS: Contrary to what is generally believed, we found in this study cohort that patients with a family history of HCC had better overall survival than those without such a history. We believe this was in part due to earlier diagnosis of the disease and better liver function in this group of patients. However, the effects of genetic factors on the risk of HCC cannot be overlooked and are yet to be identified. (Hepatobiliary Pancreat Dis Int 2012;11: ) Author Affiliations: Department of Surgery (Dai WC, Fan ST, Cheung TT, Chok KSH, Chan ACY, Tsang SHY, Poon RTP and Lo CM); State Key Laboratory for Liver Research (Fan ST, Poon RTP and Lo CM), The University of Hong Kong, 102 Pokfulam Road, Hong Kong, China Corresponding Author: Prof. Sheung Tat Fan, Department of Surgery, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, China (Tel: ; Fax: ; stfan@hku.hk) 2012, Hepatobiliary Pancreat Dis Int. All rights reserved. doi: /S (12) KEY WORDS: hepatocellular carcinoma; family history; resection; survival; risk factor Introduction Chronic infections with hepatitis B and hepatitis C viruses are the most well-established environmental risk factors for hepatocellular carcinoma (HCC) worldwide. [1] Other risk factors that have been associated with HCC development include liver cirrhosis, diabetes mellitus, alcohol consumption, cigarette smoking, aflatoxin exposure, and male sex. [2-8] Meanwhile, familial aggregation of liver cancer has been reported. [9-13] Dietary habits and other behaviors associated with HCC that cluster in families may account for some of the observed familial aggregation of the disease. Amongst studies of patients with chronic infection of hepatitis B virus, family history of HCC is also identified as a risk factor for the disease's development. Thus, genetic factors are likely to modify the risk of HCC. [14] In the literature, there are a few studies focusing on the familial risk of HCC, but the prognosis of HCC in this particular group of patients remains unclear. Methods Study design This was a retrospective study drawing on prospectively collected data involving 4532 patients aged between 18 and 97 years who were diagnosed with HCC and were subsequently managed at our center from 1989 to Upon recruitment, each patient was personally interviewed to obtain information on their sociodemographic characteristics, habits of cigarette smoking and alcohol drinking, personal medical history, and family history of HCC. HCC was staged according 160 Hepatobiliary Pancreat Dis Int,Vol 11,No 2 April 15,2012

2 Impact of family history of HCC to the United Network for Organ Sharing (UNOS) staging system. Statistical analysis All statistical analyses were performed with SPSS Categorical data were presented as number and percentage and compared by the chi-square test or Fisher's exact test where appropriate. Continuous variables were expressed as mean and standard deviation unless specified and compared by Student's t test or the Mann-Whitney U test. Overall survival of patients was determined with the Kaplan-Meier method and life tables, and significance of survival differences was determined with the log-rank test. P<0.05 was considered to be significant. Results Participants' characteristics Table 1 shows the demographic characteristics of the 4532 patients in the study. Patients with a family history Table 1. Demographic characteristics of patients with and without a family history of HCC Variables Group A (n=475) Group B (n=4057) P value Sex (male/female) 388/ / Median age (yr) 53 (18-83) 59 (18-97) < HBsAg positive 446 (94.3%) 3086 (76.8%) < Co-morbidity illness 142 (29.9%) 1522 (37.5%) Asymptomatic HCC 209 (44.0%) 1192 (29.4%) < Child-Pugh < classification A 414 (87.2%) 2825 (69.6%) B 47 (9.9%) 940 (23.2%) C 14 (2.9%) 292 (7.2%) Median AFP level on ( ) 282 ( ) diagnosis (ng/ml) Median platelet count (20-760) 168 (9-1104) ( 10 9 /L) Median serum 39 (13-53) 37 (12-54) < albumin (g/l) Median serum 14 (2-706) 17 (2-995) < bilirubin (µmol/l) UNOS staging < I 28 (5.9%) 156 (3.9%) II 144 (30.4%) 755 (18.8%) III 122 (25.7%) 941 (23.4%) IV 180 (38.0%) 2172 (54.0%) Group A: patients with a family history of HCC; Group B: patients without such history. For HBsAg positive: There are two patients in group A and 39 patients in group B with missing data. For UNOS staging: There are one patient in group A and 33 patients in group B with missing data. of HCC (n=475, group A) (median age 53 years; range years) were significantly younger than patients without such a history (n=4057, group B) (median age 59 years; range years) (P<0.0001). Significantly more patients in group A were carriers of hepatitis B virus (94.3% vs 76.8%, P<0.0001) and were asymptomatic (44.0% vs 29.4%, P<0.0001). Group A patients had significantly better liver function in terms of Child-Pugh classification and serum albumin and bilirubin levels (all with P<0.0001). In group A, 5.9%, 30.4%, 25.7% and 38.0% of patients had stage I, II, III and IV HCC respectively. The corresponding percentages in group B were 3.9%, 18.8%, 23.4% and 54.0% (P<0.0001). Management Significantly more patients in group B received transarterial chemoembolization (26.3% vs 19.8%) or conservative treatment (42.5% vs 22.5%) as palliation. On the other hand, significantly more patients in group A underwent hepatectomy (45.1% vs 22.8%) or radiofrequency ablation (11.4% vs 5.5%) as curative treatment (P<0.0001) (Table 2). Overall survival Group A had 1-, 3- and 5-year overall survival rates of Table 2. Treatment modalities for patients with and without a family history of HCC Group A (n=475) Group B (n=4057) Fig. 1. Overall survival of all patients (P<0.0001). P value Hepatectomy 214 (45.1%) 925 (22.8%) < Major 124 (57.9%) 576 (62.3%) Minor 90 (42.1%) 349 (37.7%) Radiofrequency ablation 54 (11.4%) 222 (5.5%) < Transarterial chemoembolization 94 (19.8%) 1068 (26.3%) Conservative 107 (22.5%) 1724 (42.5%) < Liver transplantation 5 (1.1%) 117 (2.9%) Microwave ablation 1 (0.2%) 1 (0.02%) Group A: patients with a family history of HCC; Group B: patients without such history. Hepatobiliary Pancreat Dis Int,Vol 11,No 2 April 15,

3 Hepatobiliary & Pancreatic Diseases International 62.7%, 43.9% and 37.2%, respectively. Group B had the corresponding rates at 45.8%, 28.2% and 20.8% (Fig. 1). The median survival was 25.7 months for group A and 9.6 Fig. 2. Overall survival of patients with major hepatectomy (P=0.446). months for group B (P<0.0001). Altogether 700 patients underwent major hepatectomy. Among them, 124 were group A patients, and they had 1-, 3- and 5-year overall survival rates of 78.8%, 57.3% and 48.3%, respectively. Group B patients (n=576) had the corresponding rates of 75.5%, 53.2% and 43% respectively (P=0.446) (Fig. 2). The two groups also showed no significant difference in disease-free survivals (P=0.748) (Fig. 3). Totally 439 patients underwent minor hepatectomy. The 1-, 3- and 5-year overall survival rates were 93.2%, 78.5% and 72.2%, respectively for group A patients (n=90) and 89.4%, 71.2% and 57.1%, respectively for group B patients (n=349) (P=0.013) (Fig. 4). There was no significant difference in disease-free survival between the two groups (P=0.463) (Fig. 5). Fig. 3. Disease-free survival of patients with major hepatectomy (P=0.748). Fig. 6. Overall survival of patients with stage I disease (P=0.041). Fig. 4. Overall survival of patients with minor hepatectomy (P=0.013). Fig. 7. Overall survival of patients with stage II disease (P=0.002). Fig. 5. Disease-free survival of patients with minor hepatectomy (P=0.463). Fig. 8. Overall survival of patients with stage III disease (P=0.002). 162 Hepatobiliary Pancreat Dis Int,Vol 11,No 2 April 15,2012

4 Impact of family history of HCC Fig. 9. Overall survival of patients with stage IV disease (P=0.057). We also analyzed the survival data according to the staging of disease (Figs. 6-9). For HCC at stages I, II and III, group A had a significantly better overall survival: stage I, 69.3 vs months, P=0.041; stage II, 61.4 vs months, P=0.002; stage III, 21.2 vs 33.0 months, P= However, for HCC at stage IV, the difference was not significant (4.5 vs 3.8 months, P=0.057). Discussion Hepatocarcinogenesis is a multi-step process that involves viral factors, host genetic factors, chemical carcinogens, and their interactions. The reported association between a family history of liver cancer and HCC could be explained by the clustering of infections of hepatitis B virus among members of the same family. However, genetic factors might also play an important role in the carcinogenesis of these familial HCCs. In the literature, there are no data regarding the survival of patients with a family history of HCC. This study compared the clinicopathological features and survival between patients with and without such a history. It is without doubt that there are some differences in demographic characteristics between group A and group B and there were confounding factors in analysis. We did not have a patient surveillance program for HCC in Hong Kong, but it is probable that patients in group A, with their family history of HCC, represented a more health-conscious population. Disease stage and treatment modality were two most important prognostic factors for survival and this was why we had separate analyses on these two factors. It was found that group A patients presented HCC at a significantly earlier age and at an earlier stage, and significantly more of them were asymptomatic. With earlier diagnosis of the disease, it is not surprising to find that more patients in this group were amenable to hepatectomy or radiofrequency ablation as the primary treatment. This may also translate into the better overall survival in this group, with a median survival of 25.7 months compared with 9.6 months in group B. However, despite earlier diagnosis, amongst patients who received hepatectomy, still more than half in each group required major resection as the primary treatment, and the overall survival after major hepatectomy was comparable between the two groups. For minor hepatectomy, on the other hand, the overall survival was significantly better in group A. Probably this is because in group A there were more patients with asymptomatic or early-stage HCC which was more amenable to minor hepatectomy. As to disease-free survival, the extent of hepatectomy made no difference and the groups fared similar. This may reflect that the natural history and biology of the disease were not altered by presentation or treatment modality. Most people would think that patients with a family history of HCC would have a worse prognosis of the disease than those without such a history. In this study, on the contrary, it was found that when the stage of disease was considered, the former group of patients had significantly better survival than the latter group, except in the case of stage IV disease. This study is the first one in the literature to demonstrate such a phenomenon. This phenomenon cannot be totally attributable to earlier diagnosis as patients with the same stage of disease were compared. As with all studies dealing with a family history of cancer, this study is not immune from recall bias, but since our data were collected prospectively, the bias effect in the two groups would be more or less equivalent. Further studies into this particular group of patients with a family history involving tumor biology and genetic analysis should be warranted. Contributors: DWC designed the study, did the statistics, analyzed the data, and drafted the manuscript. FST was responsible for the design of the study and critical revision and approval of the manuscript. CTT, CKSH, CACY and TSHY collected the data. PRTP and LCM were responsible for critical revision and approval of the manuscript. Funding: None. Ethical approval: Not needed. Competing interest: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. References 1 Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75: Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127:S Hepatobiliary Pancreat Dis Int,Vol 11,No 2 April 15,

5 Hepatobiliary & Pancreatic Diseases International 3 Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61: Yu MW, Tsai SF, Hsu KH, You SL, Lee SS, Chen CJ. Epidemiologic characteristics of malignant neoplasms in Taiwan: II. Liver cancer. J Natl Public Health Ass ROC 1988; 8: Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17: Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145: Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339: Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-asians of Los Angeles County, California. J Natl Cancer Inst 1991;83: Demir G, Belentepe S, Ozguroglu M, Celik AF, Sayhan N, Tekin S, et al. Simultaneous presentation of hepatocellular carcinoma in identical twin brothers. Med Oncol 2002;19: Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM. Segregation analysis of hepatocellular carcinoma in a moderately highincidence area of East China. World J Gastroenterol 2003;9: Zhang JY, Wang X, Han SG, Zhuang H. A case-control study of risk factors for hepatocellular carcinoma in Henan, China. Am J Trop Med Hyg 1998;59: Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30: Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92: Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology 2005;48: Received December 19, 2011 Accepted after revision February 15, Hepatobiliary Pancreat Dis Int,Vol 11,No 2 April 15,2012

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants

Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1

More information

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery

More information

RESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment

RESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,

More information

The purpose of donor interchange in living donor

The purpose of donor interchange in living donor Samaritan Case Report donor interchange in LDLT Samaritan donor interchange in living donor liver transplantation See Ching Chan, Kenneth SH Chok, William W Sharr, Albert CY Chan, Simon HY Tsang, Wing

More information

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence

More information

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and

More information

NIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.

NIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18. NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured

More information

Hepatitis B virus (HBV) infection is an important. Brief Communication

Hepatitis B virus (HBV) infection is an important. Brief Communication Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma

Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Hepatocellular Carcinoma: Can We Slow the Rising Incidence? Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good

PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision

More information

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,

More information

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 RESEARCH ARTICLE Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand Jitrapa

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

Accepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?

Accepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Accepted Manuscript Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia

More information

B C ALT B C B B C

B C ALT B C B B C 2006 17 276-290 520 ( Hepatitis surface antigen, HsAg ) ( Anti-hepatitis virus antibody anti-hv ) ( alanine transaminase ) 2004 4 11 31 533 216 (n=56702; / : 17551/39151) HsAg anti-hv 40 IU/L (standardized

More information

Hepatitis B surface antigen HBsAg Hepatitis B e antigen HBeAg 1) B

Hepatitis B surface antigen HBsAg Hepatitis B e antigen HBeAg 1) B 292 14 4 B Effects of the Vaccination Against Hepatitis B Virus for All Infants in Taiwan Chang-Kuen Tien, Nobutaka Kurihara, Hiroyuki Yanagisawa and Osamu Wada (Hygiene and Preventive Medicine, Saitama

More information

How to apply HCC prediction models to practice?

How to apply HCC prediction models to practice? How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.

More information

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age

More information

Does Viral Cure Prevent HCC Development

Does Viral Cure Prevent HCC Development Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,

More information

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy Cancer Biol Med 2013;10:158-164. doi: 10.7497/j.issn.2095-3941.2013.03.006 ORIGINAL ARTICLE Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy Yang Ke*,

More information

Ng, KKC; Poon, RTP; Chan, SC; Chok, KSH; Cheung, TT; Tung, H; Chu, F; Tso, WK; Yu, WC; Lo, CM; Fan, ST

Ng, KKC; Poon, RTP; Chan, SC; Chok, KSH; Cheung, TT; Tung, H; Chu, F; Tso, WK; Yu, WC; Lo, CM; Fan, ST Title High-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience Author(s) Ng, KKC; Poon, RTP; Chan, SC; Chok, KSH; Cheung, TT; Tung, H; Chu, F; Tso, WK; Yu, WC; Lo, CM;

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Hepatocellular Carcinoma in Qatar

Hepatocellular Carcinoma in Qatar Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study

More information

Tumor Factors Associated with Clinical Outcomes in Patients with Hepatitis B Virus Infection and Hepatocellular Carcinoma

Tumor Factors Associated with Clinical Outcomes in Patients with Hepatitis B Virus Infection and Hepatocellular Carcinoma Tumor Factors Associated with Clinical Outcomes in Patients with Hepatitis B Virus Infection and Hepatocellular Carcinoma Myron John Tong, PhD, MD, Surachate Siripongsakun, MD, Gaelen Stanford-Moore, BA,

More information

Laparoscopic Liver Resection for Hepatocellular Carcinoma

Laparoscopic Liver Resection for Hepatocellular Carcinoma Original Article Laparoscopic Liver Resection for Hepatocellular Carcinoma Carmen D. Chung, Lydia L. Lau, Kwan Lung Ko, Andrew C. Wong, Shezam Wong, Albert C. Chan, Ronnie T. Poon, Chung Mau Lo and Sheung

More information

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High

More information

Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis

Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Author's response to reviews Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Authors: Mei-Yin Zhang (zhangmy@sysucc.org.cn) Shu-Hong

More information

Treatment of HCC in real life-chinese perspective

Treatment of HCC in real life-chinese perspective Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

Hepatitis B virus (HBV) infection is a global

Hepatitis B virus (HBV) infection is a global VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

Management of HepatoCellular Carcinoma

Management of HepatoCellular Carcinoma 9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma

More information

Perceptions of cancer risk and self-care practices: comparison of groups at different risk for cancers

Perceptions of cancer risk and self-care practices: comparison of groups at different risk for cancers Title Perceptions of risk and self-care practices: comparison of groups at different risk for s Author(s) Fielding, R; Lam, WWT; Liao, Q; Lai, CL; Tsang, WHJ; Ip, DKM; Yuen, RMF Citation Hong Kong Medical

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung

간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung 간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging

More information

Gang Huang, MD; Wan Yee Lau, MD, FRCS; Wei-ping Zhou, MD, PhD; Feng Shen, MD, PhD; Ze-ya Pan, MD; Sheng-xian Yuan, MD; Meng-chao Wu, MD

Gang Huang, MD; Wan Yee Lau, MD, FRCS; Wei-ping Zhou, MD, PhD; Feng Shen, MD, PhD; Ze-ya Pan, MD; Sheng-xian Yuan, MD; Meng-chao Wu, MD Research Original Investigation Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels Gang Huang,

More information

Hepatocellular carcinoma (HCC) is the most

Hepatocellular carcinoma (HCC) is the most Original Article / Biliary Hepatobiliary & Pancreatic Diseases International Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study Ding-Ding Wang, Li-Qun

More information

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer

More information

Association between polymorphisms in the promoter region of pri-mir-34b/c and risk of hepatocellular carcinoma

Association between polymorphisms in the promoter region of pri-mir-34b/c and risk of hepatocellular carcinoma Association between polymorphisms in the promoter region of pri-mir-34b/c and risk of hepatocellular carcinoma L.L. Chen 1,2, Y. Shen 3, J.B. Zhang 4, S. Wang 5, T. Jiang 6, M.Q. Zheng 6, Z.J. Zheng 7

More information

Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases

Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases RESEARCH ARTICLE Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases Ashraf Omar Abdel Aziz 1, Dalia Omran

More information

Hepatocellular carcinoma in Sri Lanka - where do we stand?

Hepatocellular carcinoma in Sri Lanka - where do we stand? SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior

More information

SIR- RFS Journal Primer

SIR- RFS Journal Primer Comparison of Combina-on Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboliza-on with Radiofrequency Abla-on versus Microwave Abla-on SIR- RFS Journal Primer Quick Summary

More information

C hronic hepatitis B (CHB) virus infection affects more

C hronic hepatitis B (CHB) virus infection affects more 161 HEPATITIS Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications MF Yuen, HJ Yuan, D KH Wong, J CH Yuen, WM Wong, A OO Chan, B CY Wong, KC Lai, CL Lai... See end of article

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

ORIGINAL ARTICLE. Jun Zheng 1, Rong-chun Xing 1, Wei-hong Zheng 2, Wei Liu 1, Ru-cheng Yao 1, Xiao-song Li 1, Jian-ping Du 1, Lin Li 1.

ORIGINAL ARTICLE. Jun Zheng 1, Rong-chun Xing 1, Wei-hong Zheng 2, Wei Liu 1, Ru-cheng Yao 1, Xiao-song Li 1, Jian-ping Du 1, Lin Li 1. JBUON 2017; 22(3): 709-713 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A comparative study on postoperative mortality prediction of SFLI scoring

More information

Management of hepatocellular carcinoma should consider both tumor factors and background liver factors

Management of hepatocellular carcinoma should consider both tumor factors and background liver factors Hepatocellular Carcinoma Column: Editorial Management of hepatocellular carcinoma should consider both tumor factors and background liver factors Shuji Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Hiroyuki

More information

Proton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center

Proton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center Proton Beam Therapy for Hepatocellular Carcinoma Li Jiamin, MD Wanjie Proton Therapy Center 1 1 Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide It is the eighth most common neoplasm

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular

More information

ALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER

ALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon

More information

Epidemiology of hepatitis E infection in Hong Kong

Epidemiology of hepatitis E infection in Hong Kong RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epidemiology of hepatitis E infection in Hong Kong DPC Chan *, KCK Lee, SS Lee K e y M e s s a g e s 1. The overall anti hepatitis E virus (HEV) seropositivity

More information

Hepatitis B Virus-Related Hepatocellular Carcinoma Presenting at an Advanced Stage: Is it Preventable? Dr Tom Mules NZSG ASM 2018

Hepatitis B Virus-Related Hepatocellular Carcinoma Presenting at an Advanced Stage: Is it Preventable? Dr Tom Mules NZSG ASM 2018 Hepatitis B Virus-Related Hepatocellular Carcinoma Presenting at an Advanced Stage: Is it Preventable? Dr Tom Mules NZSG ASM 2018 HCC Males Females Ferlay et al. Cancer incidence and mortality worldwide:

More information

The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer

The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer European Review for Medical and Pharmacological Sciences 2017; 21: 4039-4044 The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer H.-Y. FAN

More information

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD CLINICAL OFFICES Digestive Health Liver Clinic 900 Blake Wilbur Dr MC 5355 Palo Alto, CA 94304 Tel (650) 498-7999 Fax (650) 724-9454 Liver Transplant Clinic 300 Pasteur Dr A160 Bio MC 5309 Stanford, CA

More information

Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma

Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma DOI:10.1111/j.1477-2574.2012.00507.x HPB ORIGINAL ARTICLE Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma Umut Sarpel 1, Diego Ayo 2, Iryna Lobach 3, Ruliang Xu 4

More information

Efficacy of Prophylactic Entecavir for Hepatitis B Virus- Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization

Efficacy of Prophylactic Entecavir for Hepatitis B Virus- Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization DOI:http://dx.doi.org/10.7314/APJCP.2015.16.18.8665 Efficacy of Prophylactic Entecavir for Hepatitis B Virus Related HCC Receiving Transcatheter Arterial Chemoembolization RESEARCH ARTICLE Efficacy of

More information

Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan,

Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan, Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan, 1976 2005 LONG-TENG LEE, HSIAO-YUAN HUANG, KUO-CHIN HUANG, CHING-YU CHEN, AND WEN-CHUNG LEE PURPOSE: Hepatocellular carcinoma

More information

What have we learned from HBV clinical cohorts?

What have we learned from HBV clinical cohorts? PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National

More information

Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation

Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation Title Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation Author(s) Chan, SC; Fan, ST Citation Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 2, p.

More information

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts

More information

White Nights of Hepatology 2016

White Nights of Hepatology 2016 White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow

More information

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma. Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital

More information

Hepatitis B virus X gene in the development of hepatocellular carcinoma. Citation Hong Kong Medical Journal, 2011, v. 17 n. 6, suppl. 6, p.

Hepatitis B virus X gene in the development of hepatocellular carcinoma. Citation Hong Kong Medical Journal, 2011, v. 17 n. 6, suppl. 6, p. Title Hepatitis B virus X gene in the development of hepatocellular carcinoma Author(s) Ma, NF; Lau, SH; Hu, L; Dong, SS; Guan, XY Citation Hong Kong Medical Journal, 2011, v. 17 n. 6, suppl. 6, p. 44-47

More information

Relationship Between GSTT1 Gene Polymorphism and Hepatocellular Carcinoma in Patients from China

Relationship Between GSTT1 Gene Polymorphism and Hepatocellular Carcinoma in Patients from China RESEARCH ARTICLE Relationship Between GSTT1 Gene Polymorphism and Hepatocellular Carcinoma in Patients from China Jie Chen, Liang Ma, Ning-Fu Peng, Shi-Jun Wang, Le-Qun Li* Abstract Objective: The results

More information

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department

More information

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed

More information

Effect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular invasion of hepatocellular carcinoma

Effect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular invasion of hepatocellular carcinoma Qu et al. Infectious Agents and Cancer (2019) 14:2 https://doi.org/10.1186/s13027-019-0219-8 RESEARCH ARTICLE Open Access Effect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular

More information

Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees

Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Yin-Chu Chien, 1 Chyi-Feng Jan, 2 Chun-Ju Chiang, 3 Hsu-Sung

More information

INTRODUCTION. Key Words: Carcinoma, hepatocellular; Barcelona Clinic Liver Cancer; Hong Kong Liver Cancer; Neoplasm staging.

INTRODUCTION. Key Words: Carcinoma, hepatocellular; Barcelona Clinic Liver Cancer; Hong Kong Liver Cancer; Neoplasm staging. Gut and Liver, Vol. 12, No. 1, January 218, pp. 94-11 ORiginal Article Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver

More information

Original Article Association of osteopontin polymorphism with cancer risk: a meta-analysis

Original Article Association of osteopontin polymorphism with cancer risk: a meta-analysis Int J Clin Exp Med 2015;8(11):20911-20917 www.ijcem.com /ISSN:1940-5901/IJCEM0015120 Original Article Association of osteopontin polymorphism with cancer risk: a meta-analysis Gang Yang 1, Xiaoxing Peng

More information

Gut Online First, published on May 5, 2005 as /gut

Gut Online First, published on May 5, 2005 as /gut Gut Online First, published on May 5, 2005 as 10.1136/gut.2005.069237 p53 gene (Gendicine ) and embolization overcame recurrent hepatocellular carcinoma Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. Authors

More information

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate

More information

Professor Norbert Bräu

Professor Norbert Bräu Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST

More information

Cancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006

Cancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006 Chinese Journal of Cancer Original Article Cancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006 Xiao-Pan Li 1, Guang-Wen Cao 2, Qiao

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

ABSTRACT. Shuisheng Zhang 1, Xiaozhun Huang 2, Yuan Tian 3, Saderbieke Aimaiti 1, Jianwei Zhang 1, Jiuda Zhao 4, Yingtai Chen 1 and Chengfeng Wang 1

ABSTRACT. Shuisheng Zhang 1, Xiaozhun Huang 2, Yuan Tian 3, Saderbieke Aimaiti 1, Jianwei Zhang 1, Jiuda Zhao 4, Yingtai Chen 1 and Chengfeng Wang 1 Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China Shuisheng Zhang 1, Xiaozhun Huang

More information

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite

More information

Presentation by Dr. Thomas Yau on behalf of his co-authors

Presentation by Dr. Thomas Yau on behalf of his co-authors 4078 First presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, Illinois, USA, June 3-7, 2016. Reused with permission from the American Society of Clinical Oncology

More information

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma Surveillance Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated

More information

Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis

Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis Early Detection, Curative, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis Amit G. Singal 1,2,3 *, Anjana Pillai 4, Jasmin Tiro 2,3 1 Department

More information

ORIGINAL ARTICLE. Summary. Introduction

ORIGINAL ARTICLE. Summary. Introduction JBUON 2017; 22(4): 936-941 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A propensity score-matched case-control comparative study of laparoscopic

More information

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer He et al. BMC Gastroenterology 2013, 13:87 RESEARCH ARTICLE Open Access Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer Chao-Zhu He 1,2, Kun-He Zhang

More information

Liver Transplant Program, Chang Gung Memorial Hospital, Taoyuan 33378, Taipei, China

Liver Transplant Program, Chang Gung Memorial Hospital, Taoyuan 33378, Taipei, China Original Article Salvage transplantation for post-resection recurrence in hepatocellular carcinoma associated with hepatitis C virus etiology: a feasible strategy? Bhavin Bhupendra Vasavada 1, Chao-Long

More information

Association between Traditional Chinese Medicine Use and Liver Cancer in Patients with Liver Cirrhosis: A Population-based Study

Association between Traditional Chinese Medicine Use and Liver Cancer in Patients with Liver Cirrhosis: A Population-based Study Research Article imedpub Journals http://www.imedpub.com/ Journal of Cancer Epidemiology and Prevention Association between Traditional Chinese Medicine Use and Liver Cancer in Patients with Liver Cirrhosis:

More information

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information